Plain-English translation of NCT06380907 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing ZL-1102, a new topical gel that works by targeting a specific immune protein involved in psoriasis. About 250 patients will apply different doses of the medication or a placebo gel to their skin for 16 weeks so researchers can see which dose works best and whether it is safe.
Plaque psoriasis is a chronic skin condition that can significantly impact quality of life, and while some treatments exist, researchers are looking for new topical options that may be more effective with fewer side effects.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication gel at one of several doses or a placebo gel (inactive treatment) that looks identical. You will apply your assigned gel to your affected skin areas as instructed over a 16-week treatment period. You'll have regular clinic visits to have your skin examined and to check for any side effects, and researchers will measure how well the treatment is working by assessing how much your psoriasis improves.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Australia